Skip to content
Home/Companies/Biotech/Cure51
CU

Cure51

Biotech·France·Active·2yr hold

Cure51 is a healthcare / digital health company, headquartered in France.

Entry
2024
Hold
2yr
Status
Active
Est. EV
–

Who owns Cure51?

Cure51 is currently owned by Hitachi Ventures through Hitachi Ventures Fund III (2023 vintage), since 2024. Across its history, Cure51 has been through 2 private equity ownership periods, detailed in the timeline below.

Hand-verified · updated 2026-04-21

Hitachi Ventures
Most recent investor
Hitachi Ventures
Hitachi Ventures Fund III · 2023 · VC
2 ownership periods · full history below

Key facts

HQFrance
SectorHealthcare / Digital Health

Ownership history

2 ownership periods · co-invest detected

Active
Co-held by Sofinnova Partners and Hitachi Ventures since 2024.
Co-invest · 2 holders · 2024 · present
Sofinnova Partners
Sofinnova PartnersActive
2024 · present · Sofinnova Digital Medicine I · 2022 · VC
MOIC
–
Hitachi Ventures
Hitachi VenturesActive
2024 · present · Hitachi Ventures Fund III · 2023 · VC
MOIC
–

More from Hitachi Ventures Fund III

Other portfolio companies in the same fund.

Bioptimus
Active
BiotechFrance· 2025
Archetype AI
Active
Deep TechUnited States· 2024
Cyclic Materials
Active
IndustrialsCanada· 2024
Ema
Active
SoftwareUnited States· 2024
Grow Inc
Active
FintechAustralia· 2024
Lineaje
Active
SoftwareUnited States· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings